1.67
+0.01(+0.60%)
Currency In USD
| Previous Close | 1.66 |
| Open | 1.69 |
| Day High | 1.7 |
| Day Low | 1.67 |
| 52-Week High | 46.68 |
| 52-Week Low | 1.41 |
| Volume | 25,510 |
| Average Volume | 516,491 |
| Market Cap | 4.8M |
| PE | -8.35 |
| EPS | -0.2 |
| Moving Average 50 Days | 2.3 |
| Moving Average 200 Days | 6.59 |
| Change | 0.01 |
If you invested $1000 in Calidi Biotherapeutics, Inc. (CLDI) since IPO date, it would be worth $17.08 as of October 16, 2025 at a share price of $1.67. Whereas If you bought $1000 worth of Calidi Biotherapeutics, Inc. (CLDI) shares 3 years ago, it would be worth $16.88 as of October 16, 2025 at a share price of $1.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
GlobeNewswire Inc.
Sep 29, 2025 12:00 PM GMT
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver gene
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver gene
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
GlobeNewswire Inc.
Aug 21, 2025 10:33 PM GMT
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genet